Current Pharmacology Reports最新文献_第9页

Methylxanthines as Potential Inhibitor of SARS-CoV-2: an In Silico Approach. 甲基黄嘌呤作为 SARS-CoV-2 的潜在抑制剂：一种硅学方法。

Current Pharmacology Reports Pub Date : 2022-01-01 Epub Date: 2022-03-08 DOI: 10.1007/s40495-021-00276-3

Rajan Rolta, Deeksha Salaria, Bhanu Sharma, Oladoja Awofisayo, Olatomide A Fadare, Sonum Sharma, Chirag N Patel, Vikas Kumar, Anuradha Sourirajan, David J Baumler, Kamal Dev

{"title":"Methylxanthines as Potential Inhibitor of SARS-CoV-2: an In Silico Approach.","authors":"Rajan Rolta, Deeksha Salaria, Bhanu Sharma, Oladoja Awofisayo, Olatomide A Fadare, Sonum Sharma, Chirag N Patel, Vikas Kumar, Anuradha Sourirajan, David J Baumler, Kamal Dev","doi":"10.1007/s40495-021-00276-3","DOIUrl":"https://doi.org/10.1007/s40495-021-00276-3","url":null,"abstract":"The aim of the present study was to test the binding affinity of methylxanthines (caffeine/theine, methylxanthine, theobromine, theophylline and xanthine) to three potential target proteins namely Spike protein (6LZG), main protease (6LU7) and nucleocapsid protein N-terminal RNA binding domain (6M3M) of SARS-CoV-2. Proteins and ligand were generated using AutoDock 1.5.6 software. Binding affinity of methylxanthines with SARS-CoV-2 target proteins was determined using Autodock Vina. MD simulation of the best interacting complexes was performed using GROMACS 2018.3 (in duplicate) and Desmond program version 2.0 (academic version) (in triplicate) to study the stabile interaction of protein-ligand complexes. Among the selected methylxanthines, theophylline showed the best binding affinity with all the three targets of SARS-CoV-2 (6LZG - 5.7 kcal mol-1, 6LU7 - 6.5 kcal mol-1, 6M3M - 5.8 kcal mol-1). MD simulation results of 100 ns (in triplicate) showed that theophylline is stable in the binding pockets of all the selected SARS-CoV-2 proteins. Moreover, methylxanthines are safer and less toxic as shown by high LD50 value with Protox II software as compared to drug chloroquine. This research supports the use of methylxanthines as a SARS-CoV-2 inhibitor. It also lays the groundwork for future studies and could aid in the development of a treatment for SARS-CoV-2 and related viral infections.Graphical abstract: Supplementary information: The online version contains supplementary material available at 10.1007/s40495-021-00276-3.","PeriodicalId":11139,"journal":{"name":"Current Pharmacology Reports","volume":"8 2","pages":"149-170"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8901432/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142085940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of COVID-19 on Antimicrobial Resistance in Paediatric Population: a Narrative Review. COVID-19对儿科人群抗微生物药物耐药性的影响:叙述性综述

Current Pharmacology Reports Pub Date : 2022-01-01 Epub Date: 2022-06-28 DOI: 10.1007/s40495-022-00298-5

Arya Karun, Rimple Jeet Kaur, Jaykaran Charan, Krishna Murti, M Ramesh, V Ravichandiran, Sameer Dhingra

引用次数: 1

Myricetin: a Multifunctional Flavonol in Biomedicine. 杨梅素:生物医学中的多功能黄酮醇。

Current Pharmacology Reports Pub Date : 2022-01-01 Epub Date: 2022-01-10 DOI: 10.1007/s40495-021-00269-2

Gopikrishna Agraharam, Agnishwar Girigoswami, Koyeli Girigoswami

{"title":"Myricetin: a Multifunctional Flavonol in Biomedicine.","authors":"Gopikrishna Agraharam, Agnishwar Girigoswami, Koyeli Girigoswami","doi":"10.1007/s40495-021-00269-2","DOIUrl":"https://doi.org/10.1007/s40495-021-00269-2","url":null,"abstract":"Purpose of reveiw: The root cause of many diseases like CVD, cancer, and aging is free radicals which exert their effect by interfering with different metabolic pathways. The sources of free radicals can be exogenous, like UV rays from sunlight, and endogenous due to different metabolic by-products.In our body, there are defense mechanisms present, such as antioxidant enzymes and antioxidant molecules to combat these free radicals, but if there is an overload of these free radicals in our body, the defense system may not be sufficient to neutralize these free radicals. In such situations, we are exposed to a chronic low dose of oxidants creating oxidative stress, which is responsible for eliciting different diseases.Recent findings: Pubmed and Google Scholar are the search engines used to sort out relevant papers on myricetin and its role in combating many diseases. Myricetin is present in many fruits and vegetables and is a known antioxidant. It can elevate the antioxidant enzyme levels; reduces the lipid peroxidation; and is known to protect against cancer. In the case of myocardial dysfunction, myricetin has been shown to suppress the inflammatory cytokines and reduced the mortality rate. Myricetin has also been found to reduce platelet aggregation and control the viral infections by interfering in the DNA replication pathways.Summary: In this paper, we have briefly reviewed about the different type and site of free radicals and the role of myricetin in addressing the ROS and different diseases.","PeriodicalId":11139,"journal":{"name":"Current Pharmacology Reports","volume":"8 1","pages":"48-61"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8743163/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39687674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 30

Lefamulin: a New Hope in the Field of Community-Acquired Bacterial Pneumonia. 利福霉素：社区获得性细菌性肺炎领域的新希望。

Current Pharmacology Reports Pub Date : 2022-01-01 Epub Date: 2022-07-06 DOI: 10.1007/s40495-022-00297-6

Shubham Adhikary, Meher Kaur Duggal, Saraswathy Nagendran, Meena Chintamaneni, Hardeep Singh Tuli, Ginpreet Kaur

{"title":"Lefamulin: a New Hope in the Field of Community-Acquired Bacterial Pneumonia.","authors":"Shubham Adhikary, Meher Kaur Duggal, Saraswathy Nagendran, Meena Chintamaneni, Hardeep Singh Tuli, Ginpreet Kaur","doi":"10.1007/s40495-022-00297-6","DOIUrl":"10.1007/s40495-022-00297-6","url":null,"abstract":"Purpose of review: Community-acquired bacterial pneumonia (CABP) continues to be a worldwide health concern since it is the major cause of mortality and hospitalisation worldwide. Increased macrolide resistance among Streptococcus pneumoniae and other infections has resulted in a significantly larger illness burden, which has been exacerbated by evolving demography and a higher prevalence of comorbid disorders. Owing to such circumstances, the creation of new antibiotic classes is critical.Recent findings: Lefamulin, also referred to as BC-3781, is the primary pleuromutilin antibiotic which has been permitted for both intravenous and oral use in humans for the remedy of bacterial infections. It has shown activity against gram-positive bacteria including methicillin-resistant strains as well as atypical organisms which as often implicated in CABP. It has a completely unique mechanism of action that inhibits protein synthesis via way of means of stopping the binding of tRNA for peptide transfer. The C(14) side chain is responsible for its pharmacodynamic and antimicrobial properties, together with supporting in overcoming bacterial ribosomal resistance and mutations improvement amplifying the number of hydrogen bonds to the target site.Summary: This review aims to highlight the pre-existing treatment options and specific purposes to shed some light upon the development of a new drug lefamulin and its specifications and explore this novel drug's superior efficacy to already existing treatment strategies.","PeriodicalId":11139,"journal":{"name":"Current Pharmacology Reports","volume":"8 6","pages":"418-426"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9257118/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40506572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Neuroinflammation in Epilepsy—Diagnostics and Therapeutic Perspectives 癫痫神经炎症的诊断和治疗前景

Current Pharmacology Reports Pub Date : 2021-12-08 DOI: 10.1007/s40495-021-00270-9

Piotr Lach, Wiktoria Klus, Krystian Zajdel, Adam Szeleszczuk, Ewelina Komorowska, Klaudia Burda, P. Kurowski

引用次数: 4

Hepatic Impairment Physiologically Based Pharmacokinetic Model Development: Current Challenges 基于肝功能损害生理学的药代动力学模型开发:当前的挑战

Current Pharmacology Reports Pub Date : 2021-10-01 DOI: 10.1007/s40495-021-00266-5

Agnes Nuo Han, B. Han, Tao Zhang, T. Heimbach

引用次数: 3

Author Correction: Hepatic Impairment Physiologically Based Pharmacokinetic Model Development: Current Challenges 作者更正:基于肝功能损害生理学的药代动力学模型开发:当前的挑战

Current Pharmacology Reports Pub Date : 2021-10-01 DOI: 10.1007/s40495-021-00267-4

Agnes Nuo Han, B. Han, Tao Zhang, T. Heimbach

引用次数: 2

Progression in Alzheimer’s Disease Correlates With Epigenetics and Cerebral Formaldehyde: From Potential Hereditary Mechanism and Environmental Factors to Therapeutic Measures 阿尔茨海默病的进展与表观遗传学和脑甲醛相关:从潜在的遗传机制和环境因素到治疗措施

Current Pharmacology Reports Pub Date : 2021-08-23 DOI: 10.1007/s40495-021-00265-6

M. Pant, Siddhartha Dan, Sujata Pant, Aditya Raj, S. Upadhyay

引用次数: 1

Endophytic Mycoflora: Antibacterial Secondary Metabolites and Their Therapeutic Potential 内生真菌群：抗菌次级代谢产物及其治疗潜力

Current Pharmacology Reports Pub Date : 2021-08-10 DOI: 10.1007/s40495-021-00261-w

R. P. Aharwal, Suneel Kumar, S. Sandhu

引用次数: 5

Assessment of Bacterial Pathogens in Drinking Water: a Serious Safety Concern 饮用水中细菌病原体的评估:一个严重的安全问题

Current Pharmacology Reports Pub Date : 2021-08-09 DOI: 10.1007/s40495-021-00263-8

Sunil Kumar, R. Anwer, A. Sehrawat, M. Yadav, N. Sehrawat

引用次数: 8